# Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

> **NCT07092202** · PHASE4 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 40 (estimated)

## Conditions studied

- Leptomeningeal Metastasis
- NSCLC
- Intrathecal Chemotherapy
- Tyrosine Kinase Inhibitor

## Interventions

- **DRUG:** Firmonertinib
- **DRUG:** Intrathecal injection of pemetrexed

## Key facts

- **NCT ID:** NCT07092202
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07092202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07092202, "Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07092202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*